The government has not allowed any pharmaceutical company to increase prices of drugs beyond permissible limits, parliament was told on Tuesday.
"Few companies have given representations for increasing prices of medicines beyond permissible limits mentioning various reasons like increase in cost, tax, foreign exchange rates etc. However, no company has been given permission to increase the prices so far," Minister of Chemicals and Fertilisers Ananth Kumar told the Lok Sabha.
He said the government has brought down prices of 404 medicines under the National List of Essential Medicines, 2015 (revised schedule-I) of the Drug Price Control Order (DPOC) 2013.
The government has earlier "reduced the ceiling prices of 530 medicines as on 2/3/2016 under NLEM 2011 of DPCO 2013 (original schedule-I) on the basis of the negative wholesale price index," he said.
Schedule I of DPCO 2013 contains the national list of essential medicines.
Meanwhile, the government said earlier this month that the rapidly growing Indian pharmaceutical market is expected to grow to $55 billion by 2020 and emerge as the sixth largest globally by size.
India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume.
--IANS
bc/vd
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
